Shares of Abivax (ABVX) climbed about 6% in premarket trading on Thursday after the clinical-stage biotech company announced that underwriters have fully exercised their option to purchase an additional 960,000 American depositary shares.ABVX shares are on track to hit their highest levels since De…
ABIVAX/ Key word(s): Capital IncreaseAbivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)02.07.2026 / 08:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Abivax Announces Full Exercis…
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)PARIS, France, July 2, 2026 – 8:00 a.m. CEST – Abivax SA (Euronext Paris:FR0012333284 – ABVX / NASDAQ:ABVX (“Abivax” or the “Company”), a clinical-stage biotechnol…
Abivax (ABVX) on Wednesday announced the pricing of its previously announced underwritten public offering of 6.4 million American Depositary Shares (ADSs) at an offering price of $125 apiece.The size of the offering was increased to $800 million from the previously announced $600 million, Abivax sa…
Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary SharesPARIS, France, July 1, 2026 – 2:30 p.m. (CEST) – Abivax SA (Euronext Paris:FR0012333284 – ABVX / NASDAQ:ABVX (“Abivax” or the “Company”), a clinical-stage biotechnology company f…
Abivax announces trading resumption of its ordinary shares on Euronext ParisPARIS, France, July 1, 2026 – 02:50 p.m. CEST – Abivax SA (Euronext Paris:FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s n…
ABIVAX/ Key word(s): Capital IncreaseAbivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares01.07.2026 / 14:40 CET/CESTThe issuer is solely responsible for the content of this announcement.Abivax Announces Pricing of Highly Oversubsc…
Abivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary SharesPARIS, France, July 1, 2026 – 2:30 p.m. (CEST) – Abivax SA (Euronext Paris:FR0012333284 – ABVX / NASDAQ:ABVX (“Abivax” or the “Company”), a clinical-stage biotechnology company focused…
ABIVAX/ Key word(s): MiscellaneousAbivax announces temporary trading halt of its ordinary shares on Euronext Paris01.07.2026 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.Abivax announces temporary trading halt of its ordinary shares on Euronext ParisPARIS, F…
Abivax announces temporary trading halt of its ordinary shares on Euronext ParisPARIS, France, July 1, 2026 – 07:30 a.m. CEST – Abivax SA (Euronext Paris:FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body…
Shares of Abivax (ABVX) clocked their best day in about 11 months on Tuesday on the heels of multiple price target revisions and updated safety and efficacy data from a study that addressed prior investor worries about cancer risk tied to its ulcerative colitis candidate, obefazimod.ABVX stock clos…
ABIVAX/ Key word(s): Capital IncreaseAbivax Announces Launch of Public Offering of American Depositary Shares30.06.2026 / 22:48 CET/CESTThe issuer is solely responsible for the content of this announcement.Abivax Announces Launch of Public Offering of American Depositary SharesPARIS, France – June…
Abivax Announces Launch of Public Offering of American Depositary SharesPARIS, France – June 30, 2026 – 10:45 p.m. CEST – Abivax SA (Euronext Paris:FR0012333284 – ABVX / NASDAQ:ABVX (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness t…
Abivax NASDAQ:ABVX shares jumped as much as 36% after its latest obefazimod trial update helped calm investor concerns that cancer could be a possible side effect of the biotech's key experimental ulcerative colitis drug. The company said cancer cases reported in the study were within a background…
Abivax (ABVX) stock jumped 28% in after-hours trading on Monday after the company released encouraging late-stage results for its experimental drug, obefazimod, in patients with ulcerative colitis, and eased previous safety concerns about higher cancer incidence.Encouraging Results For Hard-To-Trea…
ABIVAX/ Key word(s): Study results/StudyAbivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory UC Patients and Strengthening the Phase 3 Maintenance Safety Database29.06.2026 / 22:05 CET/CESTThe issuer is solely responsible…
Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety DatabasePARIS, France – June 29, 2026 – 10:05 pm CEST – Abivax SA (Euronext Paris:FR00123332…